06 November 2019
: Case report
Complete Response of Chemo-Refractory Metastatic Metaplastic Breast Cancer to Paclitaxel-Immunotherapy Combination
Unusual or unexpected effect of treatment, Diagnostic / therapeutic accidents, Rare disease, Educational Purpose (only if useful for a systematic review or synthesis)
Adher D. Al Sayed1DEF*, Mahmoud A. Elshenawy12BDE, Asma Tulbah3BD, Taher Al-Tweigeri1A, Hazem Ghebeh4AEFGDOI: 10.12659/AJCR.918770
Am J Case Rep 2019; 20:1630-1635
Abstract
BACKGROUND: Metaplastic breast cancer (MPBC) is a rare subtype of breast cancer that is difficult to manage and is resistant to therapy. Immunotherapy is becoming a promising option for care of several types of cancers including triple negative breast cancer.
CASE REPORT: We present a case of a patient with chemo-refractory metastatic metaplastic-type of breast cancer with failures to 3 active lines of chemotherapy. The patient achieved a complete and sustained response to chemo-immunotherapy combination with acceptable tolerability and minimal adverse events. The treatment was a combination of anti-PD-L1 antibody (durvalumab) immunotherapy in combination with the chemotherapeutic agent, paclitaxel.
CONCLUSIONS: This is the first case reporting the successful use of durvalumab and paclitaxel combination for treatment of triple negative breast cancer in general, and in metastatic MPBC in specific.
Keywords: Antigens, CD274, paclitaxel, Triple Negative Breast Neoplasms, Antibodies, Monoclonal, Antineoplastic Agents, Immunological, Antineoplastic Agents, Phytogenic, Carcinoma, Squamous Cell, Immunotherapy, Therapies, Investigational
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946588
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946011
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.945910
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.945852
Most Viewed Current Articles
21 Jun 2024 : Case report
88,859
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
50,114
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133
20 Nov 2023 : Case report
25,398
DOI :10.12659/AJCR.941424
Am J Case Rep 2023; 24:e941424
18 Feb 2024 : Case report
22,663
DOI :10.12659/AJCR.943030
Am J Case Rep 2024; 25:e943030